Eli Lilly & Co
LLY (NYSE)
Eli Lilly & Co stands out as a leader in weight management drugs with promising products like Mounjaro and Zepbound, despite a slight dip in momentum. With a robust Growth Style Score of A and an impressive forecast of 83.1% earnings growth for the current fiscal year, the company is well-positioned for future success. Investors can expect solid returns, as evidenced by a remarkable 5-year return of 400.80% and a current analyst rating of B+, with a median 12-month price target of $1,191.00.
Pros:
- Leader in weight management drugs
- Strong growth outlook
Cons:
- Recent momentum loss
- Market competition
Eli Lilly & Co (LLY) presents a compelling investment opportunity for growth-oriented investors seeking exposure to the healthcare sector, particularly in the weight management space. With a strong historical performance and positive earnings growth projections, it may be suitable for those willing to accept a lower dividend yield in exchange for potential capital appreciation.